St. George's respiratory questionnaire has longitudinal construct validity in lymphangioleiomyomatosis

Chest

Volumn 143, Issue 6, 2013, Pages 1671-1678

  Swigris, Jeffrey J ^a   Lee, Hye Seung ^b   Cohen, Marsha ^c   Inoue, Yoshikazu ^d   Moss, Joel ^e   Singer, Lianne G ^f   Young, Lisa R ^g   McCormack, Francis X ^h  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; RAPAMYCIN; VASCULOTROPIN D;

ADULT; ARTICLE; CONSTRUCT VALIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INSTRUMENT VALIDATION; LONGITUDINAL STUDY; LUNG DIFFUSION CAPACITY; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT OUTCOME; WALKING;

EID: 84878574276     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0161     Document Type: Article

References (23)

1. Cabana H, Alexandre C, Agathos SN, Jones JP. Immobilization of laccase from the white rot fungus Coriolopsis polyzona and use of the immobilized biocatalyst for the continuous elimination of endocrine disrupting chemicals. Bioresour Technol. 2009;100(14):3447-3458.
2. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis. A review. Am J Pathol. 1975;79(2):348-382.
3. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med. 1990;323(18):1254-1260.
4. Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999;160(2):628-633.
5. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest. 2004;126(6):1867-1874.
6. Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE. Survival and disease progression in UK patients with lymphangioleiomyomatosis . Thorax. 2004;59(9):800-803.
7. Ryu JH, Moss J, Beck GJ, et al NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173(1):105-111.
8. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85(suppl B):25-31.
9. Xu KF, Wang L, Tian XL, et al. The St. George's Respiratory Questionnaire in lymphangioleiomyomatosis. Chin Med Sci J. 2010;25(3):140-145.
10. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3):398-404.
11. Spencer S, Calverley PM, Sherwood Burge P, Jones PW; ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(1):122-128.
12. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010;104(2):296-304.
13. McCormack FX, Inoue Y, Moss J, et al National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis . N Engl J Med. 2011;364(17):1595-1606.
14. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A selfcomplete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321-1327.
15. ATS Committee on Proficiency Standards for Clinical Pul monary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
16. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010;138(3):674-681.
17. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res. 2000;9(8):887-900.
18. Streiner D, Norman G. Health Measurement Scales: A Practical Guide to Their Development and Use. 4th ed. New York, NY: Oxford University Press;2008.
19. Hays RD, Hadorn D. Responsiveness to change: an aspect of validity, not a separate dimension. Qual Life Res. 1992;1(1):73-75.
20. Patrick DL, Chiang YP. Measurement of health outcomes in treatment effectiveness evaluations: conceptual and methodological challenges. Med Care. 2000;38(suppl 9): II14-II25.
21. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: qualification process for drug development tools. Silver Spring, MD: Office of Communications, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration;2010.
22. de Torres JP, Casanova C, Hernández C, et al. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health Qual Life Outcomes. 2006;4:72.
23. Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. 2nd ed. New York, NY: CRC Press;2010.